Chi KN - Search Results

1

Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Stockler MR, et al. Among authors: chi kn. J Clin Oncol. 2022 Mar 10;40(8):837-846. doi: 10.1200/JCO.21.00941. Epub 2021 Dec 20. J Clin Oncol. 2022. PMID: 34928708 Free PMC article. Clinical Trial.

2

The standard of reporting of health-related quality of life in clinical cancer trials.

Lee CW, Chi KN. Lee CW, et al. Among authors: chi kn. J Clin Epidemiol. 2000 May;53(5):451-8. doi: 10.1016/s0895-4356(99)00221-8. J Clin Epidemiol. 2000. PMID: 10812316

3

Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tract.

Al-Karim HA, Tan KE, Chi KN, Bryce CJ, Murray NR, Coppin C. Al-Karim HA, et al. Among authors: chi kn. Am J Clin Oncol. 2002 Oct;25(5):515-9. doi: 10.1097/00000421-200210000-00019. Am J Clin Oncol. 2002. PMID: 12393996

4

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Ernst DS, et al. J Clin Oncol. 2003 Sep 1;21(17):3335-42. doi: 10.1200/JCO.2003.03.042. J Clin Oncol. 2003. PMID: 12947070 Clinical Trial.

5

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

Winquist E, Moore MJ, Chi KN, Ernst DS, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. Winquist E, et al. Among authors: chi kn. Urol Oncol. 2005 May-Jun;23(3):143-9. doi: 10.1016/j.urolonc.2004.12.012. Urol Oncol. 2005. PMID: 15907712 Clinical Trial.

6

A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.

Tinker A, Winquist E, Canil C, Moore M, Murray RN, Chi KN. Tinker A, et al. Among authors: chi kn. Am J Clin Oncol. 2006 Feb;29(1):3-7. doi: 10.1097/01.coc.0000200044.81711.57. Am J Clin Oncol. 2006. PMID: 16462494 Clinical Trial.

7

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators. Beer TM, et al. Among authors: chi kn. J Clin Oncol. 2007 Feb 20;25(6):669-74. doi: 10.1200/JCO.2006.06.8197. J Clin Oncol. 2007. PMID: 17308271 Clinical Trial.

8

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.

Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. Chi KN, et al. Clin Cancer Res. 2008 Feb 1;14(3):833-9. doi: 10.1158/1078-0432.CCR-07-1310. Clin Cancer Res. 2008. PMID: 18245546 Clinical Trial.

9

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Heng DY, et al. Among authors: chi kn. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826129

10

Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.

Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C, Hayes-Lattin B, Nichols C. Kollmannsberger C, et al. Among authors: chi kn. J Clin Oncol. 2010 Feb 1;28(4):537-42. doi: 10.1200/JCO.2009.23.0755. Epub 2009 Dec 21. J Clin Oncol. 2010. PMID: 20026807

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

269 results

Search Page